CN Mobile Logo


Prostate Cancer

Biomarker Combo Could Predict Prostate Cancer Survival

A combination of biomarkers has shown promise as a surrogate for survival in clinical trials of metastatic castration-resistant prostate cancer. Image © Eugene Sim / Shutterstock.com.

Prostate Cancer

Researchers have developed a blood test that can identify mutations in the androgen receptor gene that drive resistance to abiraterone. The test could identify prostate cancer patients who will not respond to the treatment.

For men with prostate cancer undergoing radiation therapy, consumption of men’s health supplements are unlikely to prevent adverse events, metastasis, or cancer-related death.

Hypofractionated radiation therapy appears to lead to similar efficacy and safety as a standard radiation therapy regimen for men with low-risk prostate cancer.

© Image Point Fr/Shutterstock.com

Risk does not go up with exposure to testosterone therapy over a 5-year period or according to total testosterone injections.

The use of bone-seeking radionuclides effectively controlled bone pain in men with prostate cancer metastatic to the bone, according to the results of a systematic review.

A new meta-analysis suggests that survival outcomes are similar with intermittent and continuous androgen deprivation therapy, and that intermittent therapy may improve some quality-of-life criteria.

Six months of radiation therapy combined with ADT for prostate cancer may not produce a survival benefit in men with moderate to severe comorbidities.


Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.